Production (Stage)
Pasithea Therapeutics Corp.
KTTA
$0.6748
-$0.0145-2.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.95M | 1.75M | 1.42M | 1.59M | 2.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.68M | 3.26M | 3.00M | 3.95M | 4.04M |
| Operating Income | -3.68M | -3.26M | -3.00M | -3.95M | -4.04M |
| Income Before Tax | -3.56M | -3.18M | -3.00M | -3.87M | -3.86M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.56M | -3.18M | -3.00M | -3.87M | -3.86M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.56M | -3.18M | -3.00M | -3.87M | -3.86M |
| EBIT | -3.68M | -3.26M | -3.00M | -3.95M | -4.04M |
| EBITDA | -3.52M | -3.10M | -2.84M | -3.78M | -3.88M |
| EPS Basic | -1.61 | -2.53 | -2.87 | -3.71 | -3.70 |
| Normalized Basic EPS | -1.01 | -1.58 | -1.80 | -2.32 | -2.31 |
| EPS Diluted | -1.61 | -2.53 | -2.87 | -3.71 | -3.70 |
| Normalized Diluted EPS | -1.01 | -1.58 | -1.80 | -2.32 | -2.31 |
| Average Basic Shares Outstanding | 2.21M | 1.25M | 1.04M | 1.04M | 1.04M |
| Average Diluted Shares Outstanding | 2.21M | 1.25M | 1.04M | 1.04M | 1.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |